Ionisos acquired French sterilisation solutions specialist Stermed with the support of its shareholder Ardian, an independent private investment company.
Based in Civrieux d’Azergues, Stermed specialises in low-temperature sterilisation using ethylene oxide. This highly technical and technological procedure requires a number of certifications and has strong growth potential, particularly driven by the medical sector.
The company offers subcontracting solutions for the treatment (decontamination and sterilisation) of medical devices (surgical instruments, implants, forceps, specula) and industrial devices (laboratory equipment). The Stermed site covers 3,200m² and is equipped with four treatment units, preconditioning chambers, desorption chambers, and a microbiological analysis laboratory.
Ardian has accompanied Ionisos in its development since July 2016, most notably through its external growth.
President of Ionisos Michel Gominet says: “Only a small number of companies in France currently have expertise in low-temperature sterilisation using ethylene oxide. The acquisition of Stermed reinforces our position in this promising market segment by expanding our geographic reach towards the south of France, the north being already covered by our Gien site.”
Managing director of Ionisos Christoph Herkens adds: “We are very familiar with Stermed and its teams. This merger reinforces our technological and industrial platform. Our geographical proximity to Stermed is also a major advantage.”
Head of the Civrieux site Matthieu Reinhardt said: “We are pleased to be joining the Ionisos group, which will enable us to continue building on our growth together, while benefiting from the Ionisos group’s expertise.”
Head of the Ardian Expansion team François Jerphagnon adds: “Ionisos is pursuing its development plan. This operation fits in perfectly with our targeted acquisition strategy. The company is establishing itself as the main player in consolidation of its market in France and Europe.”